Acute myeloid leukemia(AML) and its treatment have remained, for long, an area of slow but constant therapeutic progress as well as of permanent frustration. Chemotherapy has initially been and still is part of the ba...Acute myeloid leukemia(AML) and its treatment have remained, for long, an area of slow but constant therapeutic progress as well as of permanent frustration. Chemotherapy has initially been and still is part of the backbone of therapy.However, the high rate of relapses leading to death and the development of molecular biology with recent next generation sequencing taught us that the disease is heterogeneous with often a major leukemic clone presenting frontline but always multiple clones and subclones escaping our chemotherapy regimen and generating more aggressive relapses.展开更多
文摘Acute myeloid leukemia(AML) and its treatment have remained, for long, an area of slow but constant therapeutic progress as well as of permanent frustration. Chemotherapy has initially been and still is part of the backbone of therapy.However, the high rate of relapses leading to death and the development of molecular biology with recent next generation sequencing taught us that the disease is heterogeneous with often a major leukemic clone presenting frontline but always multiple clones and subclones escaping our chemotherapy regimen and generating more aggressive relapses.
